Cargando…
Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach
More than half of males in China are current smokers and evidence from western countries tells us that an unprecedented number of smoking-attributable deaths will occur as the Chinese population ages. We used the China Lung Cancer Policy Model (LCPM) to simulate effects of computed tomography (CT)-b...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342219/ https://www.ncbi.nlm.nih.gov/pubmed/28273181 http://dx.doi.org/10.1371/journal.pone.0173119 |
_version_ | 1782513131158765568 |
---|---|
author | Sheehan, Deirdre F. Criss, Steven D. Gazelle, G. Scott Pandharipande, Pari V. Kong, Chung Yin |
author_facet | Sheehan, Deirdre F. Criss, Steven D. Gazelle, G. Scott Pandharipande, Pari V. Kong, Chung Yin |
author_sort | Sheehan, Deirdre F. |
collection | PubMed |
description | More than half of males in China are current smokers and evidence from western countries tells us that an unprecedented number of smoking-attributable deaths will occur as the Chinese population ages. We used the China Lung Cancer Policy Model (LCPM) to simulate effects of computed tomography (CT)-based lung cancer screening in China, comparing the impact of a screening guideline published in 2015 by a Chinese expert group to a version developed for the United States by the U.S. Centers for Medicare & Medicaid Services (CMS). The China LCPM, built using an existing lung cancer microsimulation model, can project population outcomes associated with interventions for smoking-related diseases. After calibrating the model to published Chinese smoking prevalence and lung cancer mortality rates, we simulated screening from 2016 to 2050 based on eligibility criteria from the CMS and Chinese guidelines, which differ by age to begin and end screening, pack-years smoked, and years since quitting. Outcomes included number of screens, mortality reduction, and life-years saved for each strategy. We projected that in the absence of screening, 14.98 million lung cancer deaths would occur between 2016 and 2050. Screening with the CMS guideline would prevent 0.72 million deaths and 5.8 million life-years lost, resulting in 6.58% and 1.97% mortality reduction in males and females, respectively. Screening with the Chinese guideline would prevent 0.74 million deaths and 6.6 million life-years lost, resulting in 6.30% and 2.79% mortality reduction in males and females, respectively. Through 2050, 1.43 billion screens would be required using the Chinese screening strategy, compared to 988 million screens using the CMS guideline. In conclusion, CT-based lung cancer screening implemented in 2016 and based on the Chinese screening guideline would prevent about 20,000 (2.9%) more lung cancer deaths through 2050, but would require about 445 million (44.7%) more screens than the CMS guideline. |
format | Online Article Text |
id | pubmed-5342219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-53422192017-03-29 Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach Sheehan, Deirdre F. Criss, Steven D. Gazelle, G. Scott Pandharipande, Pari V. Kong, Chung Yin PLoS One Research Article More than half of males in China are current smokers and evidence from western countries tells us that an unprecedented number of smoking-attributable deaths will occur as the Chinese population ages. We used the China Lung Cancer Policy Model (LCPM) to simulate effects of computed tomography (CT)-based lung cancer screening in China, comparing the impact of a screening guideline published in 2015 by a Chinese expert group to a version developed for the United States by the U.S. Centers for Medicare & Medicaid Services (CMS). The China LCPM, built using an existing lung cancer microsimulation model, can project population outcomes associated with interventions for smoking-related diseases. After calibrating the model to published Chinese smoking prevalence and lung cancer mortality rates, we simulated screening from 2016 to 2050 based on eligibility criteria from the CMS and Chinese guidelines, which differ by age to begin and end screening, pack-years smoked, and years since quitting. Outcomes included number of screens, mortality reduction, and life-years saved for each strategy. We projected that in the absence of screening, 14.98 million lung cancer deaths would occur between 2016 and 2050. Screening with the CMS guideline would prevent 0.72 million deaths and 5.8 million life-years lost, resulting in 6.58% and 1.97% mortality reduction in males and females, respectively. Screening with the Chinese guideline would prevent 0.74 million deaths and 6.6 million life-years lost, resulting in 6.30% and 2.79% mortality reduction in males and females, respectively. Through 2050, 1.43 billion screens would be required using the Chinese screening strategy, compared to 988 million screens using the CMS guideline. In conclusion, CT-based lung cancer screening implemented in 2016 and based on the Chinese screening guideline would prevent about 20,000 (2.9%) more lung cancer deaths through 2050, but would require about 445 million (44.7%) more screens than the CMS guideline. Public Library of Science 2017-03-08 /pmc/articles/PMC5342219/ /pubmed/28273181 http://dx.doi.org/10.1371/journal.pone.0173119 Text en © 2017 Sheehan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Sheehan, Deirdre F. Criss, Steven D. Gazelle, G. Scott Pandharipande, Pari V. Kong, Chung Yin Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach |
title | Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach |
title_full | Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach |
title_fullStr | Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach |
title_full_unstemmed | Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach |
title_short | Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach |
title_sort | evaluating lung cancer screening in china: implications for eligibility criteria design from a microsimulation modeling approach |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342219/ https://www.ncbi.nlm.nih.gov/pubmed/28273181 http://dx.doi.org/10.1371/journal.pone.0173119 |
work_keys_str_mv | AT sheehandeirdref evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach AT crissstevend evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach AT gazellegscott evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach AT pandharipandepariv evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach AT kongchungyin evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach |